EntityRisk Review: What PROVEN™ Does and What to Check
EntityRisk sells PROVEN™, a health economics and forecasting platform for pharmaceutical companies. It is not a crypto product; pricing and detailed security information are not published.
Researched and written by the HelpfulCoin teamChecked 11 questions answered
The short answer
EntityRisk is worth considering if you work in biopharma and need health economics, pricing or evidence-planning models. Its PROVEN™ platform covers several relevant forecasting tasks, and the company identifies its leadership. But public pricing, detailed security practices and independent evidence of forecast performance are missing. Request a tailored quote, security terms and validation documentation before sharing sensitive data or relying on model outputs for major decisions.
Our verdict:Use with caution6.1/10
HelpfulCoin report card
Use with caution6.1/ 10 overall
Real gaps or risks: check them before you deposit.
- SafetyHow funds are held, audits, licence, incidents.
- C (5.5 out of 10)
- CostsFees, spreads, gas, house edge and bonus terms. Higher is cheaper.
- – (not graded)
- Ease of useHow easy it is for a newcomer to start, use and withdraw.
- C (5.5 out of 10)
- ReputationHow established and openly run it is.
- C (6.2 out of 10)
Grades: A 8.5+, B 7+, C 5.5+, D 4+, F below 4. A dash means the project doesn't publish enough to grade it.
Entity at a glance
- Category
- Other
- Product
- Health economics and forecasting software
- Platform
- PROVEN™
- Users
- Pharmaceutical and biopharma companies
- Crypto
- No token or crypto deposits described
- Pricing
- Not published
- CEO
- Neal Masia
- Last checked
Green flags and red flags
Reassuring
- EntityRisk identifies its CEO and names members of its board.
- The platform is described as a decision-support product, not a crypto custody or investment service.
- EntityRisk describes model audit reports and automated quality checks.
Be careful about
- EntityRisk does not publish pricing or standard contract terms.
- Public details do not establish its cybersecurity certifications or data-retention practices.
- The stated automated model checks do not independently prove forecast accuracy.
What is EntityRisk and what can you do with PROVEN™?
EntityRisk is a business-to-business health economics and analytics company, not a crypto exchange, token or DeFi app. Its PROVEN™ platform helps pharmaceutical companies model health outcomes, assess possible drug prices and forecast the value of evidence-generation plans. The company says its models can combine clinical trial and real-world data, compare several value-assessment frameworks and run scenarios for different product profiles and markets. The intended users are biopharma teams working on pricing, market access, product development and evidence planning. PROVEN™ includes tools named OutcomesML™, ValueML™, EvidenceML™, PriceML™ and CommercialML™. Access appears to be arranged through a meeting with EntityRisk rather than a public self-serve signup. If you are looking to hold, trade or earn yield on crypto, this product is not designed for that.
Is EntityRisk safe to use for pharmaceutical data?
EntityRisk is not a place to deposit or withdraw money, and its platform is not described as holding customer crypto or funds. That removes the usual exchange-custody risk, but it does not answer the separate question of how the company protects business or health-related data. EntityRisk describes PROVEN™ as transparent and says it includes audit reports and 1,300 automated quality checks for its models. Those are claims about model quality and analytical processes, not evidence of an independent cybersecurity audit or a financial-services licence. The company does not publish security certifications, its data-retention practices or detailed access controls in the information presented. Before sharing confidential trial, commercial or patient-related data, ask for its security documentation, data-processing terms, hosting details and incident-response process. Do not treat model checks as a guarantee that a forecast is correct.
Is EntityRisk a legitimate company?
EntityRisk presents itself as an operating company serving pharmaceutical businesses, and it says 10 of the top 20 biopharma companies work with it. Its CEO is named as Neal Masia, and its board includes Jeffrey B. Kindler and Frank D’Amelio. These details provide some identifiable leadership context, but the customer claim is not accompanied by named customers or independently verifiable contract details in the information presented. EntityRisk does not publish a founding date, a detailed company history, or a public track record of forecast accuracy. It also does not publish an independent cybersecurity audit or financial-services licence; the latter is not the type of licence usually associated with a health economics software provider. The company appears credible enough to warrant a business inquiry, but a buyer should still perform normal vendor, reference, security and legal diligence before relying on it for important pricing or evidence decisions.
How much does EntityRisk PROVEN™ cost?
EntityRisk does not publish prices, subscription rates, implementation charges or a standard fee schedule for PROVEN™. The platform is marketed to pharmaceutical companies, and the site directs prospective customers to arrange a meeting with its experts, so a buyer will need to request a tailored commercial proposal. Do not assume that access is free or that there is a fixed public subscription price. Ask whether the quote covers software access, model development, local market adaptation, data preparation, training and ongoing support; these may have different costs in enterprise software engagements. Also clarify the contract term, renewal conditions, usage limits and any charges for adding products, markets or users. Without a published price or a defined package, it is not possible to compare EntityRisk’s total cost with other vendors from the outset.
How do you get started with EntityRisk PROVEN™?
To start, a pharmaceutical company would contact EntityRisk to arrange a meeting and discuss its product, evidence and modeling needs. The platform’s stated workflow is to bring clinical-trial data, real-world data or a target product profile into disease models, then run analyses for outcomes, value, pricing, evidence priorities or commercial forecasts. Its named modules cover different tasks: OutcomesML™ predicts health outcomes; ValueML™ models value-based prices and cost-effectiveness; EvidenceML™ links product characteristics and evidence to outcomes; PriceML™ forecasts possible prices; and CommercialML™ models revenue and risks. EntityRisk says the models can be adapted across products and geographies and updated with new data. These descriptions do not establish that every client receives every module or that setup is automatic. Ask for a demonstration using a suitable sample, validation methods, required data formats, implementation responsibilities and the human review process.
Can you deposit or withdraw money from EntityRisk?
There are no crypto deposits, wallet connections or withdrawals described for EntityRisk. PROVEN™ is a business analytics platform, not a financial account, so you would not send cryptocurrency to it or withdraw a balance from it. Any payments for access or services would be handled under a commercial agreement, but EntityRisk does not publish the payment methods, invoicing schedule, fees or refund terms. It also does not publish account limits or a public user verification process. Ask the company how billing works, which legal entity signs the contract, and what happens to access and data when a contract ends. If a website or person claiming to represent EntityRisk asks you to connect a crypto wallet or transfer tokens, treat that as inconsistent with the product described and verify the request through an independently confirmed company contact before taking action.
How reliable are EntityRisk’s forecasts and model checks?
PROVEN™ is aimed at forecasting and decision support, not at replacing clinical research, payer judgment or regulatory review. EntityRisk says its models can work with small datasets and early-stage product profiles, which could help teams explore uncertainty before extensive evidence is available. That also makes it important to understand assumptions and limitations: a model’s output depends on its inputs, chosen methods and the quality of the underlying data. The company describes audit reports and automated checks, but does not publish enough detail to assess their scope or independently verify forecast accuracy. Before using a result in a pricing, trial-design or market-access decision, ask for model documentation, validation results, uncertainty ranges, sensitivity analyses and an explanation of how external evidence is incorporated. A forecast should be treated as one input to a decision, not as a guaranteed outcome.
What does EntityRisk’s PROVEN™ platform include?
EntityRisk presents PROVEN™ as a customizable platform built around a unified, parameterized disease model, with a Python core and modules for outcomes, pricing, value, evidence and commercial forecasts. It says teams can run multiple value-assessment frameworks at once, adapt models for different geographies and update models as new data arrives. That breadth may suit larger biopharma organizations managing complex products or multiple markets. However, the company does not publish public access tiers, pricing, security certifications or detailed technical documentation. Buyers should establish what is included in their proposed deployment, how custom models are governed, who can inspect or change assumptions, and whether outputs can be exported for independent review. The advertised model quality checks are not a substitute for testing the specific model against the intended use case and data.
Before you deposit: a quick checklist
- Request security and data-processing documentation before sharing confidential or patient-related data.
- Ask for a written quote covering setup, software access, support, market adaptations and renewals.
- Request model documentation, validation results and uncertainty analyses for your intended use case.
- Confirm the contract’s data ownership, retention, deletion and access terms.
5 steps
How to get started with Entity
- 1
Contact EntityRisk to discuss your product, data and modeling goals.
- 2
Request a demonstration and a written proposal that specifies included modules and services.
- 3
Review data security, confidentiality, retention and deletion terms before sharing sensitive information.
- 4
Ask for model documentation and validation relevant to your intended decisions.
- 5
Agree on billing, contract duration, support and data handling in writing before onboarding.
Plain English
Jargon explained
- Health economics model
- A model estimating health outcomes, costs or disease progression using data and stated assumptions.
- TPP
- A target product profile: a planned summary of a medicine’s intended characteristics.
- HTA
- Health technology assessment, which evaluates a treatment’s value for healthcare systems.
- Real-world data
- Real-world data collected outside controlled clinical trials, such as routine care records.
Quick answers about Entity
Does EntityRisk have a cryptocurrency token?
No. EntityRisk describes PROVEN™ as health economics and pharmaceutical analytics software, not a token, exchange or DeFi service.
What are the PROVEN™ modules?
The described modules are OutcomesML™, ValueML™, EvidenceML™, PriceML™ and CommercialML™. Ask EntityRisk which modules are included in a specific proposal.
Who is EntityRisk PROVEN™ designed for?
EntityRisk promotes its software to biopharma companies and their teams working on pricing, evidence, market access and product development.
Compare
Entity alternatives
Thunderbird is a free, open-source email app for desktop and Android, not a crypto or email-hosting service.
Obsidian is a free local-first notes app, not a crypto product; it is useful for portable notes, with plugin and device-security caveats.
GeneratorPicks is a generator buying-guide site with a sizing calculator; useful for research, but verify its recommendations independently.
Colosseum runs crypto hackathons and a startup accelerator; founders may find it useful, but should verify funding terms before committing.
Bonfire is a print-on-demand merch platform with no inventory requirement; it may suit sellers, but check costs and payout terms first.
DIGIT is a Scottish technology news and events site; it is useful for sector updates, but its operator and some service terms are unclear.
Same category
More Other dApps
Star Duke appears to mean Duke DAREC, a university digital-asset research library, not a crypto app or investment service.
Rekt is an active crypto investigative journalism site worth exploring, but verify important claims and check its payment terms before subscribing.
MoneyHero compares personal-finance products across four Asian markets; it is useful for research, but check provider terms and fees.
Galler is a free 3D virtual art museum with galleries, tours, and personal spaces; it is worth exploring, with privacy and membership details to check.
Every.Farm turns farm imagery and field data into analyses and maps; its research links are promising, but pricing and data safeguards need checking.
Lightyear is a regulated investing app with stocks, funds, crypto and variable-rate Savings; compare its fees and protections before depositing.
Where the answers come from
Sources
- dictionary.com/browse/entity(opens in a new tab)
- dictionary.cambridge.org/dictionary/english/entity(opens in a new tab)
- merriam-webster.com/dictionary/entity(opens in a new tab)
Last checked . Something wrong or out of date? Let us know and we will fix it.